

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6786269

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LI CHEN	04/19/2021
SHUANG REN	04/19/2021
JIAYI ZHANG	04/19/2021
RECEIVING PARTY DATA	
Name:	HUA MEDICINE (SHANGHAI) LTD.
Street Address:	275 AI DI SHENG ROAD
City:	PUDONG, SHANGHAI
State/Country:	CHINA
Postal Code:	201203
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17236393
CORRESPONDENCE DATA	
Fax Number:	(212)755-7306
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	wtokmakidis@jonesday.com, ipuentes@jonesday.com
Correspondent Name:	JONES DAY
Address Line 1:	250 VESEY STREET
Address Line 2:	ATTN: WENDY TOKMAKIDIS
Address Line 4:	NEW YORK, CALIFORNIA 10281-1047
ATTORNEY DOCKET NUMBER:	14633-002-999
NAME OF SUBMITTER:	ISAAC PUENTES
SIGNATURE:	/Isaac Puentes/
DATE SIGNED:	06/28/2021
Total Attachments: 2	
source=14633-002-999_Executed_Assignment_Inventors_to_Hua#page1.tif	
source=14633-002-999_Executed_Assignment_Inventors_to_Hua#page2.tif	

ASSIGNMENT

WHEREAS, WE, Li Chen, citizen of People's Republic of China, having a mailing address of No. 2 Chexin Highway, Building C-40, Songjiang, Shanghai 201612, China, residing at Shanghai, China, Shuang Ren, citizen of People's Republic of China, having a mailing address of 780 Cailun Road, Pudong, Shanghai 201203, China, residing at Shanghai, China, and Jiayi Zhang, citizen of People's Republic of China, having a mailing address of 780 Cailun Road, Pudong, Shanghai 201203, China, residing at Shanghai, China. ASSIGNORS, are the inventors of the invention in TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR for which a provisional application for a Patent of the United States has been filed.

- ☒ which is identified by Jones Day docket no. 14633-002-888 (CAM 588822-888002)
☒ which was filed on April 22, 2020, Application No. 63/013,914

and WHEREAS, HUA Medicine (Shanghai) Ltd., having an office for the transaction of business at 275 Ai Di Sheng Road, Pudong, Shanghai 201203, China, ASSIGNEE, is desirous of obtaining our entire right, title and interest in, to and under the said invention and the said application:

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, we, the said ASSIGNORS, have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said invention, and the said United States provisional application and all applications claiming priority thereto under 35 U.S.C. § 119(e) and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof; and all right to sue for infringement including past infringement.

AND WE HEREBY authorize and request the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant and agree that we have full right to convey the entire interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND WE HEREBY further covenant and agree that we will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries.

IN TESTIMONY WHEREOF, We hereunto set our hands and seals the day and year set opposite our respective signatures.

Date April 19, 2021 Li Chen L.S.

Date April 19, 2021 Ting Wu Witness 1 - Signature

Ting Wu Witness 1 - Printed Name

Date April 19, 2021 Jijiang Xu Witness 2 - Signature

Jijiang Xu Witness 2 - Printed Name

Date April 19, 2021 Shuang Ren L.S.
Shuang Ren

Date April 19, 2021 Tina Wu
Witness 1 - Signature

Tina Wu
Witness 1 - Printed Name

Date April 19, 2021 Yuejiao Duan
Witness 2 - Signature

Yuejiao Duan
Witness 2 - Printed Name

Date April 19, 2021 Jiayi Zhang L.S.
Jiayi Zhang

Date April 19, 2021 Zhouyi Pei
Witness 1 - Signature

Zhouyi Pei
Witness 1 - Printed Name

Date April 19, 2021 Chengrong Bao
Witness 2 - Signature

Chengrong Bao
Witness 2 - Printed Name

ACCEPTED AND AGREED TO BY ASSIGNEE, HUA Medicine (Shanghai) Ltd.:

Signature: [Signature] Date: April 19

Printed Name: Li Chen

Title: CEO